Close Menu

Abbott

Qiagen discussed what's in store after a failed bid by Thermo Fisher Scientific, and COVID-19 remained a hot topic on the second day of the virtual conference.

The blood test runs on Abbott's i-Stat Alinity platform and returns results within 15 minutes, the company said.

Based on the results of the new studies, the Norwegian company is positioning its calprotectin test as an alternative to conventional ELISAs.

The company will use eMed's digital health platform and expects to deliver and administer 30 million tests in Q1 2021, ramping up to 90 million in Q2.

The test will be available on Abbott's Architect and Alinity I platforms and quantitatively measures the number of antibodies a patient has.

Test capacity, particularly for rapid antigen testing, is set to explode in Q1 2021, but home and asymptomatic assays remain few and far between.

Abbott has terminated its prior $5 billion credit agreement also with JP Morgan reached in November 2018.

The deal comes one week after the Netherlands said it was buying 9.2 million of the tests. The Canadian government is also purchasing 2,172 BD Veritor Plus Systems.

The test uses the sTRA biomarker to differentiate between different subtypes of pancreatic cancer, including those that are resistant to chemotherapy.

News items for the in vitro diagnostic industry for the week of Oct. 19, 2020.

Pages